Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)

被引：0
|
作者：
Mélanie Dos Santos
Justine Lequesne
Alexandra Leconte
Stéphane Corbinais
Aurélie Parzy
Jean-Marc Guilloit
Sharmini Varatharajah
Pierre-Emmanuel Brachet
Marine Dorbeau
Dominique Vaur
Louis-Bastien Weiswald
Laurent Poulain
Corentin Le Gallic
Marie Castera-Tellier
Marie-Pierre Galais
Bénédicte Clarisse
机构：
[1] UNICANCER,Clinical Research Department
[2] Centre François Baclesse,Department of Medical Oncology
[3] UNICANCER,Department of Surgery
[4] Centre François Baclesse,Department of Pathology
[5] UNICANCERCentre François Baclesse,Department of Cancer Biology and Genetics
[6] UNICANCERCentre François Baclesse,undefined
[7] UNICANCERCentre François Baclesse,undefined
[8] UNICANCER,undefined
[9] Centre François Baclesse,undefined
[10] Normandie University,undefined
[11] UNICAEN,undefined
[12] ANTICIPE,undefined
[13] ORGAPRED Platform,undefined
来源：
BMC Cancer | / 22卷
关键词：
Gastric cancer; Gastroesophageal junction cancer; Neoadjuvant treatment; Immunotherapy; Spartalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
    Dos Santos, Melanie
    Lequesne, Justine
    Leconte, Alexandra
    Corbinais, Stephane
    Parzy, Aurelie
    Guilloit, Jean-Marc
    Varatharajah, Sharmini
    Brachet, Pierre-Emmanuel
    Dorbeau, Marine
    Vaur, Dominique
    Weiswald, Louis-Bastien
    Poulain, Laurent
    Le Gallic, Corentin
    Castera-Tellier, Marie
    Galais, Marie-Pierre
    Clarisse, Benedicte
    BMC CANCER, 2022, 22 (01)
  • [2] Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
    Dos Santos, M.
    Lequesne, J.
    Piessen, G.
    Desgrippes, R.
    Guimbaud, R.
    Pernot, S.
    Bouche, O.
    Hiret, S.
    Soularue, E.
    Dahan, L.
    Tougeron, D.
    Borg, C.
    Le Sourd, S. M.
    Samalin-Scalzi, E.
    Tellier-Castera, M.
    Leconte, A.
    Clarisse, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S856 - S856
  • [3] Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands
    Geerts, Julie F. M.
    Pape, Marieke
    Vissers, Pauline A. J.
    Verhoeven, Rob H. A.
    Mostert, Bianca
    Wijnhoven, Bas P. L.
    Rosman, Camiel
    Hellemond, Irene E. G. van
    Nieuwenhuijzen, Grard A. P.
    van Laarhoven, Hanneke W. M.
    EUROPEAN JOURNAL OF CANCER, 2025, 214
  • [4] The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
    Anter, Abeer Hussien
    Abdel-Latif, Rasha Mohamed
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [5] The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
    Abeer Hussien Anter
    Rasha Mohamed Abdel-Latif
    Medical Oncology, 2013, 30
  • [6] Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4): A multice
    Moenig, St.
    Al-Batran, S. E.
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 19 - 20
  • [7] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
    Salah-Eddin, Al-Batran
    Claudia, Pauligk
    Nils, Homann
    Harald, Schmalenberg
    Hans-Georg, Kopp
    Martin, Haag Georg
    Barbara, Luley Kim
    Wolff, Schmiegel H.
    Gunnar, Folprecht
    Stephan, Probst
    Nicole, Prasnikar
    Peter, Thuss-Patience C.
    Jorg, Trojan
    Oliver, Goetze Thorsten
    Johannes, Meiler
    Martin, Schuler H.
    Elke, Jaeger
    Ralf-Dieter, Hofheinz
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Perioperative Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin (FLOT) in Patients with Gastric or Esophagogastric Junction Adenocarcinoma; Real-Life Experience
    Yildiz, Fatih
    Eraslan, Emrah
    Ilhan, Aysegul
    Demir, Hacer
    Demir, Nazan
    Erdur, Erkan
    Yildirim, Ozgen Ahmet
    Kanmaz, Huseyin
    Aslan, Ferit
    Tufan, Gulnihal
    Durnali, Ayse
    Oksuzoglu, Berna
    Demirci, Umut
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2020, 30 (03): : 155 - 161
  • [9] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    Al-Batran, S-E.
    Pauligk, C.
    Homann, N.
    Schmalenberg, H.
    Kopp, H-G.
    Haag, G. M.
    Luley, K.
    Folprecht, G.
    Probst, S.
    Thuss-Patience, P.
    Trojan, J.
    Koenigsmann, M.
    Lindig, U.
    Pohl, M.
    Kasper, S.
    Hler, M. Mo
    Goetze, T.
    Schuler, M.
    Jaeger, E.
    Hofheinz, R. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome
    Atci, Muhammed M.
    Secmeler, Saban
    Sakin, Abdullah
    Arici, Serdar
    Can, Orcun
    Selvi, Oguzhan
    Cekin, Ruhper
    Yasar, Nurgul
    Geredeli, Caglayan
    Cihan, Sener
    INDIAN JOURNAL OF CANCER, 2024, 61 (04) : 714 - 721
12345